GSK's Lynavoy (linerixibat) Approved by US FDA for Cholestatic Pruritus in PBC
Summary
GSK announced that the US FDA has approved Lynavoy (linerixibat) for cholestatic pruritus in adult patients with primary biliary cholangitis (PBC), marking the first US approval for this indication.
Key Events
-
US FDA Approval Received
Lynavoy (linerixibat) has been approved by the US FDA for the treatment of cholestatic pruritus in adult patients with primary biliary cholangitis (PBC).
-
First-in-Class Treatment
Lynavoy is the first medicine approved in the US for this specific indication, addressing a significant unmet medical need for patients experiencing debilitating itch.
-
Approval Based on Phase III Data
The approval is supported by positive data from the global GLISTEN phase III trial, which demonstrated rapid and sustained improvements in cholestatic pruritus.
-
Follows Recent Licensing Agreement
This approval comes after GSK's March 9th announcement of a licensing agreement with Alfasigma S.p.A. for worldwide rights to linerixibat, with the transaction still ongoing.
Analysis
This FDA approval for Lynavoy (linerixibat) is a significant positive for GSK, validating its R&D capabilities in liver disease. Lynavoy is the first medicine approved in the US for cholestatic pruritus in primary biliary cholangitis (PBC) patients, addressing a substantial unmet medical need for a debilitating condition. While GSK previously licensed worldwide rights to Alfasigma, this regulatory milestone enhances the value of that ongoing agreement and could trigger significant milestone payments or royalties for GSK, strengthening its financial outlook related to this asset.
At the time of this filing, GSK was trading at $52.20 on NYSE in the Life Sciences sector, with a market capitalization of approximately $104.7B. The 52-week trading range was $32.38 to $61.70. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.